Intellect Neurosciences, Inc (OTCBB: ILNS),announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company’s ANTISENILIN® antibodies and products being developed by the Company for the treatment of Alzheimer’s disease... Intellect Neurosciences' Press Release -
Friday, April 25, 2008
Intellect Neurosciences : ... Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer’s Disease
April 11, 2008 - Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer’s Disease
Intellect Neurosciences, Inc (OTCBB: ILNS),announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company’s ANTISENILIN® antibodies and products being developed by the Company for the treatment of Alzheimer’s disease... Intellect Neurosciences' Press Release -
Intellect Neurosciences, Inc (OTCBB: ILNS),announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company’s ANTISENILIN® antibodies and products being developed by the Company for the treatment of Alzheimer’s disease... Intellect Neurosciences' Press Release -
